Effect of miR27a on Proliferation and Invasion in Colonic Cancer Cells

Yang Gao*, Bao-Dong Li, Yong-Gang Liu

Abstract

The aim of this study was to detect the expression of miR196a, miR146a, miR27a and miR200a in patients with colon cancer, and to investigate the effect of miR27a expression on proliferation and invasion in colonic cancer cells. RT-PCR was employed to detect the expression levels in colon cancers. Then, colon cancer cells were cultured and transfected with 100 nM of miR27a mimics (80 nmol/L) or 80 nM miR27a inhibitors (80 nmol/L) in 24-well plates. Proliferation and invasion of colonic cancer cells were then determined by CCK-8 and Transwell assays, respectively. Our data showed miR27a to be high-expressed in patients with colon cancer. In addition, proliferation and invasion in the miR27a mimic group were significantly higher than in the control group and negative group (P<0.05), while, proliferation and invasion in the miR27a inhibitor group were obviously lowered (P<0.05). In conclusion, high expression of miR27a may play an important role in enhancing proliferation and invasion of colon cancer cells.

Keywords: Colon cancer cells - miR27a - proliferation - invasion
colon cancer. LoVo cell line was maintained in RPMI 1640 (Gibco, Grand Island, NY, USA) supplemented with 10% FCS (Gibco, Grand Island, NY, USA) and 50 mg/ml penicillin/ streptomycin(Gibco, Grand Island, NY, USA) in a humidified incubator containing 5% CO$_2$ at 37 °C. Cells were fed three times a week and passaged every 7 days. LoVo was purchased from Saimo Company, Xuzhou, China.

**Transfection**

For increasing the transfection efficiency, we carried out an assay to analyse the transfection concentration. 24 h before transfection LoVo cells were seeded per well in 24 well plate and allowed to grow overnight. The cells were then transfected with five different concentration of Transfection Control (Cy3) (40 nM, 60 nM, 80nM, 100 nM and 120 nM, respectively) using lipofectamine 2000 (Invitrogen, Carlsbad, USA) according to the manufacture’s protocol. 24 h after transfection miR27a expression level would be detected by PCR.

After determining the optimization concentration, we further performed another transfection assay. LoVo cells were divided in 5 groups: Control group that was without any treatment, Liposome group that was transfected by lipofectamine 2000 only, Negative (RiBoBio Inc., Guangzhou, China) group, miR27a mimics (RiBoBio Inc., Guangzhou, China) group and miR27a inhibitors (RiBoBio Inc., Guangzhou, China) group. 24 h before transfection LoVo cells were seeded per well in 6 well plate and allowed to grow overnight. The cells were then transfected with Negative or 100 nM of miR27a mimics (80 nmol/L ) or 80 nM miR27a inhibitors (80 nmol/L ) using lipofectamine 2000 according to the manufacture’s protocol. 6 h after transfection, medium was replaced with fresh RPMI 1640 containing 10% FCS. 24–48 h after culturing, transfected cells were collected for further analysis. This assay was repeated for 3 times.

**Proliferation assay**

Proliferation assay was carried out in triplication experiments using cell counting kit-8 (CCK-8). 4×10$^4$ LoVo cells were seeded per well in 96 well plate and allowed to grow overnight. Then, 24 h, 48h and 72h, respectively after transfection LoVo cells were treated with

**Results**

**Expression of miR196a, miR146a, miR27a and miR200a in colon cancer tissues**

No statistically significant was found between the expression levels of miR196a, miR146a and miR200a in Normal, Colitis and Colon cancer groups (P>0.05) (Figure 1A, B, C, D). As shown in Figure 1C, miR27a expression in Colon cancer group was much higher than Normal and Colitis groups (P<0.05), while, there was no difference of miR27a expression between Normal group and Colitis group (P>0.05).

**Analysis of transfection concentration**

In miR27a mimics group, miR27a expression was gradually increased when transfection concentration of miR27a mimics raised, reaching the highest at 80nM and then getting into the plateau if keep on raising (Figure 2A). However, the miR27a level of miR27a inhibitors group was gradually decreased with the raise of miR27a inhibitors concentration, reaching the lowest at 100nM and then would be equability if keep on raising (Figure 2B).

**Effect of miR27a on proliferation in colonic cancer cells**

As shown in Figure 3, proliferation rate in miR27a mimics group was significantly higher than Negative group (P<0.05), whereas, the proliferation rate of miR27a inhibitors group was obviously lower compared to that of

**Invasion assay**

Invasion assay was carried out in triplication experiments using Transwell chambers (Millipore, Boston, MA, USA). 24 h after transfection, the cells were centrifuged and washed by PBS for 1~2 times and then suspended with L-15 containing 0.1% BSA. Then, 1×10$^5$/ mL cells were then performed with the standard Transwell protocol according to the manufacturer’s instructions. Moreover, selected cells would be observed by inverted microscope. And finally, the number of the cells would be counted. This assay was repeated for 3 times.

**Statistical analysis**

Statistical analysis was performed using SPSS 17.0 (SPSS Inc, Chicago, IL, USA). All values were expressed as mean± SD. P<0.05 was considered as statistically significant.
Asian Pacific Journal of Cancer Prevention, Vol 14, 2013

Effect of miR27a on Proliferation and Invasion in Colonic Cancer Cells

Cancer Cells

Figure 3. Effect of miR27a on Proliferation in Colonic Cancer Cells

Figure 4. Effect of miR27a on Invasion Colonic Cancer Cells

Cancer Cells

miR27a had been reported to regulate cell growth and development has been demonstrated in a few studies. miR27a is located at chromosome 19 and has been shown to be expressed in breast cancer, gastric adenocarcinoma and cervical cancer (Mertens-Talcott et al., 2007; Wang et al., 2008; Liu et al., 2009). It has been identified as an oncogenic miRNA, and its important role in cancer development has been demonstrated in a few studies. miR27a had been reported to regulate cell growth and division in a dose-dependent manner (Liu et al., 2009; Lerner et al., 2011), and it might mediate the drug resistance of esophageal cancer cells (Zhang et al., 2010) and ovarian cancer cells (Li et al., 2010). But reports about the expression of miR27a in human colon cancer were few.

In this study, we firstly used a RT-PCR approach to detect the miR27a level in human colon cancer. Our result has demonstrated that miR27a level of Colon cancer group was much higher than that of Normal and Colitis groups (P<0.05). A recent study suggested that miR27a may have a high expression level in gastric cancer (Liu et al., 2013). This is similar with the result made in our paper.

With the purpose of determining the transfection efficiency, we carried out an assay to analysis the transfection concentration. Figure 2 showed that there was a significant correlation between expression level of miR27a and concentrations of miR27a mimics and miR27a inhibitors. We finally obtained that the optimization transfection concentration of miR27a mimics was 80nM, and miR27a inhibitors was 100 nM.

Proliferation assay was performed and results showed that the proliferation rate in miR27a mimics group were significantly higher than Negative group (P<0.05). The result indicated that miR27a may enhance colon cancer cell proliferation strongly. On the other hand, we further utilized miR27a inhibitors for repression of LoVo cells growth, proliferation and invasion. The results of Transwell assay suggested that miR27a may also reinforce the invasion of colon cancer cells obviously. Tumor invasion and metastasis contribute to the great majority of cancer deaths. Our efforts towards the diminution of the disease should include developing novel biomarkers to use in screening for patients with a high risk of metastasis.

In conclusion, our data for the first time indicated that up-regulation of miR27a may play an important role in enhancing the proliferation and invasion of colon cancer cells. Meanwhile, further investigation would be necessary for identification of the exact mechanism through which miR27a influence the colon cancer cells proliferation and invasion.

Acknowledgements

The author(s) declare that they have no competing interests.

References

Bullock MD, Pickard KM, Nielsen BS, et al (2013). Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis, 4, e684.

Fendler A, Jung K (2013). MicroRNAs as new diagnostic and prognostic biomarkers in urological tumors. Crit Rev Oncog, 18, 289-302.

Filipowicz W, Bhattacharyya SN, Sonenberg N (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet, 9, 102-14.

Gargalionis AN, Basdra EK (2013). Insights in microRNAs Biology. Curr Top Med Chem, 13, 1493-502.

Kahler C, Kalluri R (2013). Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl), 91, 431-7.

Kong X, Du Y, Wang G, et al (2011). Detection of differentially expressed microRNAs in serum of pancreatic ductal
Yang Gao et al

adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. *Dig Dis Sci*, 56, 602-9.
Lerner M, Lundgren J, Akhoondi S, et al (2011). MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. *Cell Cycle*, 10, 2172-83.
Li Z, Hu S, Wang J, et al (2010). MiR-27a modulates MDR1/Pglycoprotein expression by targeting HIPK2 in human ovarian cancer cells. *Gynecol Oncol*, 119, 125-30.
Li Y, Li W, Ouyang Q, et al (2011). Detection of lung cancer with blood microRNA-21 expression levels in Chinese population. *Oncol Lett*, 2, 991-4.
Li M, Marin-Muller C, Bharadwaj U, et al (2009). MicroRNAs: control and loss of control in human physiology and disease. *World J Surg*, 33, 667-84.
Liu D, Sun Q, Liang S, et al (2013). MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells. *Mol Med Rep*, 7, 642-8.
Liu T, Tang H, Lang Y, et al (2009). MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. *Cancer Lett*, 273, 233-42.
Lucas K, Raikhel AS (2013). Insect microRNAs: biogenesis, expression profiling and biological functions. *Insect Biochem Mol Biol*, 43, 24-38.
Mertens-Talcott SU, Chintharlapalli S, Li X, et al (2007). The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. *Cancer Res*, 67, 11001-11.
Mohammed Abba, Heike Allgayer (2009). MicroRNAs as regulatory molecules in cancer: a focus on models defining miRNA functions. *Drug Discov Today Dis Model*, 6, 13-9.
Okayama H, Schetter AJ, Harris CC (2012). MicroRNAs and inflammation in the pathogenesis and progression of colon cancer. *Dig Dis*, 30, 9-15.
Rothschild SI (2013). Epigenetic Therapy in Lung Cancer - Role of microRNAs. *Front Oncol*, 3, 158.
Samimi H, Zaki Dizaji M, Ghadami M, et al (2013). MicroRNAs networks in thyroid cancers: focus on miRNAs related to the fascin. *J Diabetes Metab Disord*, 12, 31.
Schepeler T, Reinert JT, Ostenfeld MS, et al (2008). Diagnostic and prognostic microRNAs in stage II colon cancer. *Cancer Res*, 68, 6416-24.
Schultz NA, Andersen KK, Roslind A, et al (2012). Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index. *World J Surg*, 36, 2699-707.
Wang X, Tang S, Le SY, et al (2008). Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. *PLoS One*, 3, e2557.
Yan Z, Li J, Xiong Y, et al (2012). Identification of candidate colon cancer biomarkers by applying a random forest approach on microarray data. *Oncol Rep*, 28, 1036-42.
Zhang J, Guo H, Qian G, et al (2010). Mir-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network. *Mol Cancer*, 9, 211.
Zhang H, Li M, Han Y, et al (2010). Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. *Dig Dis Sci*, 55, 2545-51.
Zhao L, Bode AM, Cao Y, et al (2012). Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. *Carcinogenesis*, 33, 2220-7.